Population Pharmacokinetics and Exposure-Response Analysis for the CTLA-4 Inhibitor Tremelimumab in Metastatic NSCLC Patients in the Phase III POSEIDON Study.
Jimmy Zhijian HeVincent DuvalPetra JauslinAntonio GonçalvesAburough AbegesahChunling FanKyoungSoo LimXuyang SongCecil ChenXiaojin ShiHelen MannLee KrugSong RenAlex PhippsMegan GibbsDiansong ZhouPublished in: Clinical pharmacology and therapeutics (2023)
Blockade of CTLA-4 by tremelimumab combined with anti-PD-L1 durvalumab and chemotherapy provided increased antitumor activity and long-term survival benefits in first-line metastatic non-small-cell lung cancer (mNSCLC) in the Phase III POSEIDON study. We performed population pharmacokinetic modeling for tremelimumab using data from 1605 patients across six studies (including POSEIDON) in multiple tumors (lung cancer, bladder cancer, malignant mesothelioma, and other solid tumors), and identified a 2-compartment model with linear and time-varying clearance for tremelimumab. Cox proportional hazard regression models were applied to 326 patients with mNSCLC from POSEIDON to evaluate the association between exposure metrics and efficacy endpoints, adjusting for baseline prognostic covariates. Improved progression-free survival (PFS) and overall survival (OS) in the tremelimumab arm (in combination with durvalumab and chemotherapy) was associated with higher tremelimumab exposure (e.g. minimum concentration at 5 th dose [C min,dose5 ] and area under the curve at 5 th dose [AUC dose5 ]). However, further case-matching analyses yielded hazard ratios for the comparison of tremelimumab-treated patients in the C min,dose5 quartile 1 (Q1) subgroup with matched chemotherapy-treated patients of 1.04 (95% CI: 0.76-1.44) for OS and 0.99 (95% CI: 0.72-1.36) for PFS, suggesting that the observed apparent exposure-response relationship might be confounded. No relationship between tremelimumab exposure and safety (grade ≥ 3 treatment-emergent adverse events [AEs], AEs of special interest, or discontinuation due to AEs) was identified. These results support the consistent benefit observed with tremelimumab 75 mg every 3 weeks for up to 5 doses in combination with durvalumab and chemotherapy in POSEIDON as first-line therapy for mNSCLC.
Keyphrases
- end stage renal disease
- newly diagnosed
- ejection fraction
- phase iii
- chronic kidney disease
- small cell lung cancer
- prognostic factors
- squamous cell carcinoma
- free survival
- clinical trial
- peritoneal dialysis
- computed tomography
- locally advanced
- patient reported outcomes
- magnetic resonance imaging
- magnetic resonance
- deep learning
- big data
- smoking cessation
- clinical evaluation